nach oben

memo - Magazine of European Medical Oncology

Erschienen in:

01.12.2023 | editorial

HER2 in focus—gastric cancer

verfasst von: Dr. Aysegül Ilhan-Mutlu

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 4/2023

Einloggen, um Zugang zu erhalten

Excerpt

Human epidermal growth factor receptor 2 (HER2) was the first molecule targeted by monoclonal antibodies in solid disease. Interestingly, the first patients with disseminated HER2-positive metastatic breast cancer who received the anti-HER2 drug trastuzumab in phase I trials in the early 1990s are still alive (Siddhartha Mukharjee, The Emperor of All Maladies, A Biography of Cancer, Scribner, New York, NY, USA). This opened the door for several investigations to identify other biomarkers for targeted therapies, which significantly changed the treatment armamentarium of several types of cancer. …

Vorheriger Artikel ASCO 2023—partnering with patients: the cornerstone of cancer care and research

Nächster Artikel Prostate cancer special—part 1

Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687-97.

Ilhan-Mutlu A. Second line treatment of HER2 positive advanced gastroesophageal adenocarcinoma: past, present and future. memo. 2023;16(4).

Roider-Schur S, Machat S, Öhler L. Fast and significant response to Her2-directed therapy in the 5th line in a patient with HER2-positive metastatic adenocarcinoma of the gastroesophageal junction—A case report. memo. 2023;16(3).

Titel: HER2 in focus—gastric cancer
verfasst von: Dr. Aysegül Ilhan-Mutlu
Publikationsdatum: 01.12.2023
Verlag: Springer Vienna
Erschienen in: memo - Magazine of European Medical Oncology / Ausgabe 4/2023
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-023-00925-x

Springer Medizin Österreich

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2023

Prostate cancer special—part 1

Editorial

Management of malignant hypercalcemia in cancer patients—a short review

Essential news from ASCO 2023 in primary resectable and advanced or metastatic pancreatic cancer

WNT3 and LEF1 as markers for diagnosis and survival prediction in chronic lymphocytic leukemia patients

ASCO 2023—partnering with patients: the cornerstone of cancer care and research